Skip to content
Screener

Revvity RVTY Life Sciences — Segment operating income

Similar metrics at other companies

STERIS logo
STELife Sciences: — Segment operating income
$61.8M+6.4%
STERIS logo
STESegment operating income — Segment operating income
$343.1M+7.2%
Baxter International logo
BAXReportable Segment — Segment operating income
$298M-25.5%
Walt Disney logo
DISEntertainment Segment — Segment operating income
$1.68B+64.4%
Walt Disney logo
DISExperiences Segment — Segment operating income
$3.02B+19.9%
Walt Disney logo
DISSports Segment — Segment operating income
$858M-17.3%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$12.83B+28.7%
Enterprise value$15.91B+28.6%
P/E53.5×+18.6×
P/S4.4×+0.9×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentOperatingIncome.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000031791-26-000019
Line itemApril 5, 2026 / Life SciencesApril 5, 2026 / DiagnosticsApril 5, 2026 / TotalMarch 30, 2025 / Life SciencesMarch 30, 2025 / DiagnosticsMarch 30, 2025 / Total
Segment cost of revenue131,574156,753119,321135,190
Segment selling, general and administrative expenses94,66890,19287,09489,891
Segment research and development expenses31,62426,20628,26925,271
Segment operating income$103,979$76,122180,101$105,711$74,015179,726
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177
Acquisition and divestiture-related costs(282)(2,541)

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's life sciences — segment operating income?
Revvity (RVTY) reported life sciences — segment operating income of $103.98M in Q1 2026.
How has Revvity's life sciences — segment operating income changed year-over-year?
Revvity's life sciences — segment operating income decreased by 1.6% year-over-year, from $105.71M to $103.98M.
What is the long-term trend for Revvity's life sciences — segment operating income?
Over 3 years (2022 to 2025), Revvity's life sciences — segment operating income has grown at a -3.1% compound annual growth rate (CAGR), from $503.24M to $458.26M.
What does life sciences — segment operating income mean?
The profit generated by the Life Sciences segment after deducting cost of revenue, operating expenses, and R&D from total segment revenue. It measures the core operational profitability of the business unit before interest and taxes.

Ask your AI about Revvity's life sciences — segment operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude